LivingGLP1
Study S000814

Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

ClinicalTrials.gov record

Registration

Registration
NCT03884075
Study type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Phase
PHASE2
Masking
NONE
Status
RECRUITING
Enrollment
104
Start
2019-07-24
Primary completion
2027-09-03
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
Non-Alcoholic Steatohepatitis; Non-Alcoholic Fatty Liver Disease
Interventions
DRUG:Semaglutide
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
OTHER:19-DK-0072

Registered primary outcomes

  • Histological Improvement [30 weeks]
  • Clinical Improvement [30 weeks]
  • Change in hepatic gene expression [2 hours after an oral 75g glucose load]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0040528From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis
Manik Aggarwal, Clinical Liver Disease
2023OtherPMID 36938314DOIcites ClinicalTrials.gov:NCT03884075